Breaking News
1 hour ago
Simantini Singh Deo
Revagenix doses first participant in Phase 1 trial of Rev-56 for non-cystic fibrosis bronchiectasis.
Simantini Singh Deo
Cato Healthcare Supply appoints Ryan F. Zackon as President and Chief Executive Officer.
Simantini Singh Deo
Medicus Pharma receives FDA clearance to launch registrational Phase 2b SkinJect trial for Gorlin Syndrome.
Simantini Singh Deo
Lexicon Pharmaceuticals completes patient enrollment in pivotal Phase 3 SONATA-HCM trial.
Simantini Singh Deo